EC approves Cabotemyx as second-line treatment for thyroid cancer patients

The EC has approved the use of Cabotemyx (cabozantinib) as a monotherapy for the treatment of adult patients with locally advanced or metastatic differentiated thyroid carcinoma (DTC).

The treatment is recommended for patients refractory or not eligible to radioactive iodine, who have progressed during or after prior systemic therapy. This approval is the first-of-its-kind in Europe for this uncommon condition, with limited treatment options currently available should patients progress after prior use of systemic therapy.

Jaume Capdevila, MD, PhD, Medical Oncologist at the Vall d´Hebron University Hospital and Vall d'Hebron Institute of Oncology (VHIO), Barcelona, and a trial investigator, said, “The nature of radioiodine-refractory differentiated thyroid cancer means that this condition does not respond to the most commonly used standard of care for differentiated thyroid cancer.

“As a result, people living with this form of the disease have had limited treatment options should their disease progress. I am pleased to see the entrance of a new innovative treatment in Cabometyx, following limited progress for patients in this area for such a significant amount of time and I look forward to sharing more positive conversations with my patients on the number of options available to them.”

Steven Hildemann, MD PhD, Executive Vice President, CMO, Head of Global Medical Affairs and Global Patient Safety at Ipsen, added, “Confirmation of the approval of Cabometyx for this difficult-to-treat cancer is welcome news for patients and treating physicians. We are delighted that the European Commission has recognised the strength of the COSMIC-311 data and the possibilities that Cabometyx can deliver for people living with radioactive-iodine-refractory differentiated thyroid cancer.

We are committed to researching areas of oncology with high unmet medical needs and this decision exemplifies our ambition to bring meaningful new treatments that have the potential to make tangible differences to people’s lives.”

Lina Adams